ProAxsis Limited has closed a £1.8 million investment to support its innovative respiratory disease diagnostics and attract strategic partners.
The funding round demonstrates robust financial backing for its cutting-edge diagnostic solutions.
ProAxsis is a commercial medtech company, with a focus on respiratory diagnostics. It has developed a range of products incorporating their patented technology aiding the identification of Active proteases – validated biomarkers of disease activity.
The fundraising was led and syndicated by EMV Capital.
Read more here.